Ashish M. Kamat - Concepedia

Author

Ashish M. Kamat

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

A KAMAT, A Kamat, A M Kamat, A. Kamat, A. M. Kamat, A.M. Kamat, ASHISH KAMAT, ASHISH M. KAMAT, Al-Ahmadie, Hikmat A., Ashish M. Kamat

1.1K

Publications

30.3K

Citations

H-Index

142

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center The University of Texas Southwestern Medical Center Memorial Sloan Kettering Cancer Center Johns Hopkins University Baylor College of Medicine

About

Ashish M. Kamat is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	46	118	7.2K
2	Health Sciences	12	12	376
3	Public Health	8	8	320
4	Natural Sciences	1	1	20
5	Social Sciences	1	1	17

Ashish M. Kamat

254

Publications

18.6K

Citations

H-Index

Page 1

	Year	Citations
Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration Vitaly Margulis, Shahrokh F. Shariat, Surena F. Matin, Cancer	2009	1.1K
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Sam S. Chang, Bernard H. Bochner, Roger Chou, The Journal of Urology	2017	920
CTLA-4 blockade increases IFNγ-producing CD4 <sup>+</sup> ICOS <sup>hi</sup> cells to shift the ratio of effector to regulatory T cells in cancer patients Chrysoula I. Liakou, Ashish M. Kamat, Derek Ng Tang, Proceedings of the National Academy of Sciences	2008	535
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, The Lancet Oncology UrologySurgical OncologyGenitourinary CancerMedicinePembrolizumab Monotherapy	2021	513
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial Bradley Curtis Carthon, Jedd D. Wolchok, Jianda Yuan, Clinical Cancer Research	2010	456
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicineRepeat-dose Clinical Trial	2020	412
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma Jianjun Gao, Neema Navai, Omar Alhalabi, Nature Medicine Surgical OncologyUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2020	300
ZKSCAN3 Is a Master Transcriptional Repressor of Autophagy Santosh Chauhan, Goodwin G. Jinesh, Swati Chauhan, Molecular Cell Cell AutophagySignaling PathwayMaster Transcriptional RepressorAutophagyLipophagy	2013	269
Micropapillary bladder cancer Ashish M. Kamat, Colin P. Dinney, Jason Gee, Cancer	2007	258
Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita Jeremy Yuen‐Chun Teoh, Junjie Huang, Wendy Yuet-Kiu Ko, European Urology	2020	248

Page 1